340B Advocacy Alliance Bulletin
The Centers for Medicare & Medicaid Services July 19 released its calendar year 2022 outpatient prospective payment system/ambulatory surgical center proposed rule.
Congress is currently considering legislation that would provide temporary relief for any hospitals participating in the 340B program that had to leave the program due to patient mix changes as a result of the COVID-19 pandemic.
Congress is currently considering legislation that would provide temporary relief for any hospitals participating in the 340B program that had to leave the program due to changes in their patient mix as a result of the COVID-19 pandemic.
The Supreme Court of the United States today decided to take up AHA’s petition asking to reverse a federal appeals court decision that significantly cuts payments to certain hospitals that participate in the 340B Drug Pricing Program, threatening access to care in communities.
HRSA will continue enforcement actions against drug manufacturers and contract pharmacy arrangements
The AHA 340B Advocacy Alliance Wednesday, June 16, at 2:30 p.m. ET will host a special call for AHA 340B hospital members to provide an update on the latest activity on the 340B Drug Pricing Program.
The AHA 340B Advocacy Alliance June 16 at 2:30 p.m. ET will host a special call for AHA 340B hospital members to provide an update on the latest activity on the 340B Drug Pricing Program. AHA staff will provide updates on regulatory, legislative and legal actions related to the 340B program.
Please contact your members of Congress and urge them to support legislation that will provide certainty to hospitals participating in the 340B Drug Pricing Program during the COVID-19 public health emergency. The COVID-19 pandemic has resulted in many hospitals experiencing a reduction in…
Responding to AHA and other health care groups’
The AHA and five other health care organizations today sent a letter to Health and Human Services Secretary Xavier Becerra urging him to stop the actions of six drug companies that are denying 340B discounts on prescription drugs sold to hospitals treating a large percentage of low-income and rural…